Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Warning Letter
  6. /
  7. Hunan Norchem Pharmaceutical Co. Ltd.
WARNING LETTER
•Hunan Norchem Pharmaceutical Co. Ltd.•July 28, 2017

Hunan Norchem Pharmaceutical Co. Ltd. – FDA Warning Letter, Jul 28, 2017

Record Details

The FDA inspected Hunan Norchem Pharmaceutical Co. Ltd. in Jinshi, Hunan, China, from July 24-28, 2017, and identified significant deviations from current Good Manufacturing Practice (CGMP) for Active Pharmaceutical Ingredients (API). As a result, the firm's API are considered adulterated under section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act. The FDA found the firm's August 18, 2017, response, which claimed discontinuation of (b)(4) base manufacturing for the U.S. market and transfer of operations, to be inadequate in demonstrating compliance. Key violations included the failure to prepare and use complete production and control records for API batches, with numerous batch records for (b)(4) base being untraceable, and the approval of batch records with inaccurate raw material weights. Additionally, the firm failed to maintain complete analytical raw data for laboratory tests, citing data deletion after an instrument transfer. These deficiencies highlight a lack of understanding of basic compliant manufacturing operations, including adequate documentation, trained personnel, and written procedures. Consequently, the firm was placed on Import Alert 66-40 on October 18, 2017. The FDA may withhold approval of new applications and continue to refuse admission of articles manufactured by the firm into the U.S. The company must investigate these deviations, determine their causes, and implement corrective actions, providing a written response within 15 working days.

Company
Hunan Norchem Pharmaceutical Co. Ltd.
Inspection date
July 28, 2017
Product type
Drugs
Office
Center for Drug Evaluation and Research
Person
  • Francis Godwin (Director)
View Company Profile

ID · 56cdd073-1f12-4bb9-872b-6be8202a4d4d

Violation Codes4
FD&C Act 801(a)(3)21 CFR 211FD&C Act 501(a)(2)(B)21 U.S.C. 351(a)(2)(B)

Full citation text and observation details available on the Dashboard.

Other documents for Hunan Norchem Pharmaceutical Co. Ltd.
  • 483 - 2017-07-28July 28, 2017

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Hunan Norchem Pharmaceutical Co. Ltd.
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.